Showing 5051-5060 of 7584 results for "".
- Allergies to Pre-Moistened Wipes on the Risehttps://practicaldermatology.com/news/20140303-allergies_to_pre-moistened_wipes_on_the_rise/2459326/A preservative in pre-moistened hand wipes may be linked to a rise of allergic reactions, according to dermatologist Matthew Zirwas, MD at the Ohio State University Wexner Center. He says manufacturers are increasing use of the preservative as they reduce their dependence on formaldehyde and para
- Ellman to Launch PelleFirm at Annual Meeting of the AADhttps://practicaldermatology.com/news/20140227-ellman_to_launch_pellefirm_at_annual_meeting_of_the_aad/2459327/Ellman International, Inc., received FDA clearance to market its new PelleFirm RF Body Treatment System. The PelleFirm System is CE Marked for body skin tightening and cellulite reduction. In addition, it also has received FDA 510(K) clearance for tissue heating and the temporar
- Indoor Tanning Among High Schoolers Linked to Other Risky Behaviorhttps://practicaldermatology.com/news/20140227-indoor_tanning_among_high_schoolers_linked_to_other_risky_behavior/2459329/A national survey of high school students found that indoor tanning is a common practice, particularly among female, older and non-Hispanic white students, and is associated with several other risky health-related behaviors, according to a study by Gery P. Guy Jr., PhD, MPH of t
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr
- Promius Pharma, LLC Introduces Dr. Reddy's Authorized Generic Producthttps://practicaldermatology.com/news/20140225-promius_pharma_llc_introduces_dr_reddys__authorized_generic_product/2459331/Promius Pharma, LLC, launched its first Authorized Generic (AG) of Cloderm® Cream through its parent company Dr. Reddy's Laboratories on February 14. The AG is identical in formulation to Cloderm® Cream and will provide all the similar benefits, while increasing access and reducing pharmacy call
- Registration Open for Dermatology Nurses' Associaion's 32nd Annual Conventionhttps://practicaldermatology.com/news/20140221-registration_open_for_dermatology_nurses_associaions_32nd_annual_convention/2459335/The Dermatology Nurses' Association's 32nd Annual Convention will be held Thursday, May 1, 2014 through Sunday, May 4, 2014 at the Walt Disney World Swan and Dolphin Hotel, in Orlando, FL. Online registration is
- ZO Skin Health Announces New International Facultyhttps://practicaldermatology.com/news/20140219-zo_skin_health_announces_new_international_faculty/2459338/ZO Skin Health, Inc. announced the addition of a distinguished group of international physicians to its world-class multidisciplinary ZO faculty. Comprised of select p
- ASDS Survey Finds Skin Cancer, Cosmetic Procedures Jump 22 Percent in 2013https://practicaldermatology.com/news/20140213-asds_survey_finds_skin_cancer_cosmetic_procedures_jump_22_percent_in_2013/2459342/Dermatologic surgeons performed nearly 22 percent more medically necessary and cosmetic procedures in 2013 than the previous year, according to statistics released by the American Society for Dermatologic Surgery (ASDS). The survey was conducted January 2 thro
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- Valeant Pharmaceuticals Announces FDA Approval of Retin-A Micro Microsphere 0.08%https://practicaldermatology.com/news/20140131-valeant_pharmaceuticals_announces_fda_approval_of_retin-a_micro_microsphere_008/2459353/The FDA approved Valeant Pharmaceuticals' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA ha